References

References

Bryant AK, McKay RR, Kader AK, Parsons JK, Einck JP, Kane CJ, Mundt AJ, Murphy JD, Rose BS, Sub-castrate testosterone nadir and clinical outcomes in intermediate or high-risk localized prostate cancer, International Journal of Radiation Oncology • Biology • Physics (2019), doi: https://doi.org/10.1016/j.ijrobp.2018.12.001

ELIGARD® (leuprolide acetate) for injectable suspension, 7.5 mg, 22.5 mg, 30 mg, 45 mg prescribing information. Fort Collins, CO: Tolmar Therapeutics, Inc.; 2019

Kaisary, et al., Br J Urol. 1991

Kamada S, et al., J. Urol. 2015

Klotz L, et al., J Clin Oncol 2015

Lin, et al., Urology 1994

Nabid et al., Eur Urol Suppl 2017

National Comprehensive Cancer Network, NCCN Guidelines: Prostate Cancer, Version 4.2019: National Comprehensive Cancer Network website. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed January 2019

Oefelein, et al., Urology 2000

Parmar, et al., Br J Urol 1987

Pieczonka C, et al., Rev Urol 2018

Prettyman, Urologic Nursing 2019

Rick FG, et al., Urol Oncol. 2015

Rohl, et al., Scand J Urol Nephrol 1992

Sartor O. Eur Urol 2006

Shore N, et al., BJU Int. 2016

Soloway, et al., Urology 1991

Suzman, Antonarakis, J Clin Oncol 2016

Vogelzang, et al., Urology 1995

IMPORTANT SAFETY INFORMATION

Expand Minimize

ELIGARD®, (leuprolide acetate) for injectable suspension, is indicated for the palliative treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

See package insert for full prescribing and safety information.

Please see full Prescribing Information for ELIGARD and full Prescribing Information for ELIGARD with Pre-connected Syringe System.